OPERATIONal EXCELLENCE, SUPERIOR DELIVERY
Running clinical trials is an orchestrated process — trust PPD to conduct every trial with operational excellence. PPD partners with biopharmaceutical and biotech companies, investigators, site staff, lab and technology vendors, and regulatory authorities to reinforce patient safety and access throughout every phase of research. All play a part in delivering the quality data that can drive promising compounds forward.
EXCEEDING TIMELINES IS A HUGE MOTIVATOR FOR US.
For patients, each day saved in the drug development process represents much more than shifting points on a timeline. Time saved means time to feel better, to share with loved ones and friends, to pursue meaningful work and to achieve personal goals. In some cases, a day saved can mean time to participate in a new clinical trial for the next medical breakthrough.
THE DIFFERENCE AT PPD IS A CULTURE OF ACCOUNTABILITY.
“Our approach is to continually improve, optimize and innovate so we can run clinical trials faster, in the most efficient way possible, never compromising on patient safety or data quality.”
PPD was named the 2019 winner of the CRO Quality Award by the Association of Clinical Research Professionals (ACRP) and The Avoca Group.
“Site personnel rated PPD highly for responsive, high-quality communication, clinical research associates with strong knowledge of the study protocol and several aspects of study execution, including reliability of clinical supplies, ease of use of the electronic data capture (EDC) system and study closeout.”
From optimized protocols that incorporate the patient voice to expanding the availability of off-hour appointments and patient concierge services, we listen to patients and sites, and offer solutions to eliminate logistical barriers.
PPD uses digital technology and home health nurses to capture data where the patients spend the most time: in their homes.
Increasing Patient Diversity in Clinical Trials
PPD is focused on using data and technology to improve trial recruitment and increase the availability of clinical trial options to all communities.
Increasing diversity is key to the development of medical products and devices that are safer and more effective for everyone who will use them. Clinical trial participants should represent the target population of patients affected by a specific disease or condition.
The ability to forecast performance is central to PPD’s site selection process. We don’t select sites based only on surveys and unreliable methodology, hoping the sites have the required patients. Instead, we harness big data to more quickly guide site selection and recruitment planning.